Brett Good provides advice to companies on federal tax and employee benefit matters, including equity incentive plans, executive compensation arrangements, qualified retirement plans, and health and welfare plans.
Brett’s practice includes:
Prior to rejoining Bass, Berry & Sims, Brett was an associate with Goodwin Procter LLP in Silicon Valley.
American Health Law Association (AHLA)
National Association of Stock Plan Professionals (NASPP)
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.
Representation of King’s Daughters Health System in its joint venture partnership with UK HealthCare, the clinical health care system of the University of Kentucky, that will create new opportunities for both organizations to better serve patients throughout Kentucky, southern Ohio and West Virginia
Representation of Family Care Center, a provider of outpatient psychiatry services to the U.S. Armed Forces, veterans, and the surrounding communities, in its sale to Revelstoke Capital Partners, a Denver-based private equity firm
Representation of the University of Pittsburgh Medical Center (UPMC) in the spinoff and sale of the management services organization responsible for the operational and strategic management of Chartwell to CarepathRx, a platform company formed by Nautic Partners that offers pharmacy solutions to patients undergoing complicated medication therapies. Nautic will manage the UPMC pharmacy moving forward. Terms of the transaction were not disclosed.
Representation of OptionOne, a specialty pharmacy providing home and alternate-site infusion therapies through a comprehensive clinical approach to patient care, in its sale to Amerita, Inc., a specialty infusion company focused on providing complex pharmaceutical products and clinical services to patients outside of the hospital. Terms of the transaction were not disclosed.
Representation of J. Knipper and Company, Inc. – one of the largest suppliers of end-to-end pharmaceutical samples management services and a Court Square portfolio company – and its affiliates, including KnippeRx, in its acquisition of Eagle Pharmacy – a Florida-based full-service, direct-to-patient (DTP) pharmacy. This strategic transaction for KnippeRx will expand the company’s pharmacy programs, scale and automation capabilities.
Representation of Addus HomeCare Corporation (Nasdaq: ADUS), the nation’s largest public provider of personal home care and support services, in its definitive agreement to acquire Queen City Hospice, LLC, and its affiliate Miracle City Hospice, LLC for a cash purchase price of $192.0 million
Representation of Triage Consulting Group, a healthcare revenue integrity company in its acquisition by Revint Solutions, a leader in technology-enabled revenue integrity solutions for healthcare providers
Representation of MSouth Equity Partners, a private equity firm with a focus on lower middle market management buyouts, in its acquisition of iBenefit Communication, a benefit communication, engagement, and enrollment services company
Representation of Lineagen, Inc., a provider of molecular diagnostics services for individuals showing clinical presentations consistent with neurodevelopmental disorders, in its sale to Bionano Genomics, Inc. (Nasdaq: BNGO), a genome analysis company providing tools and services to scientists and clinicians conducting genetic research and patient testing, for $9.6 million